DBV Technologies SA Sponsored ADR DBVT 深 沪
等待开盘 06-26 09:30:00 美东时间
16.00
+0.400
+2.56%
华盛通- 最 高16.715
- 今 开16.09
- 成交量 70.15万股
- 最 低 15.35
- 昨 收 15.60
- 总市值 300.80万
- 52周最高 26.185
- 市盈率 静 --
- 换手率 373.11%
- 52周最低 8.51
- 委 比 0.45%
- 总股本 0.00亿
- 历史最高 50.57
- 量 比 2.00
- 振 幅 8.75%
- 历史最低 0.42
- 每 手 1
- 风险率 4.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多DBV Technologies Starts Infant Study of Peanut Allergy Patch
DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced that the first participant has been screened in the THRIVE Phase 2 clinical study evaluating the efficacy and safety of the
06-03 16:24
The Insider Report: A Tape Fitting for the Holiday
Market Overview We're in the middle of holiday trading here, so this is going t...
2025-12-29 02:06
Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing
DBV Technologies reports positive Phase 3 data for its VIASKIN Peanut patch in children, supporting a planned U.S. BLA filing in 2026.
2025-12-17 21:49
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
DBV Technologies' 2025 Combined General Meeting held on June 11, 2025, in Châtillon, France, resulted in shareholders approving all proposed resolutions. The company, focused on developing treatments for food allergies using its Viaskin™ platform, continues clinical trials for peanut allergies in toddlers and children.
2025-06-11 20:30
JMP Securities Reiterates Market Outperform on DBV Technologies, Maintains $5 Price Target
JMP Securities analyst Jonathan Wolleben reiterates DBV Technologies (NASDAQ:DBVT) with a Market Outperform and maintains $5 price target.
2024-09-24 21:58
